Agilent Unveils Unique Portfolio to Advance Immunotherapy

Innovative solutions provide cell-based analysis tools for translational research and development

Agilent Technologies today announced the launch of a unified product portfolio for immunotherapy researchers

"Immunotherapy is changing the cancer treatment landscape, but most of the tools available have been adapted because they were not designed for this cell-centric workflow," said Dr.

Carl June, MD, professor of immunotherapy at Penn's Perelman School of Medicine and Abramson Cancer Center, said: "Now, with the tools provided by Agilent, we can analyze flow cytometry, the dynamics of metabolism in living cells, Research to measure and quantify the ability of T cells to kill targets over time to find the answers we need

The Cell Analysis business is one of Agilent's key strategic initiatives and is critical to understanding disease and discovering potential treatments

AgilentSureGuide chemically synthesized sgRNA: Provides the best guide to realize the full potential of CRISPR in cell engineering and immunotherapy

NovoCyte Quanteon Flow Cytometer: Quickly and accurately perform immunophenotyping with up to 25 fluorescence channels using the most sensitive silicon photomultiplier detector technology on the market

xCELLigence RTCA eSight: Capture dynamic cell behavior and track biological behaviors that may not be detected by time-consuming and laborious end-point assays, enabling real-time quantitative analysis of important events such as cancer cell killing

Agilent Seahorse XF Analyzer: Study and tune immune cell metabolism for durable and reliable antitumor responses

Agilent Symposium, "Breakthroughs in Immunotherapy: Tuning the Drivers of Immune Cell Potency, Fate, and Persistence," by David Ferrick, Sunday, May 12, 10:00–10:45 am at the San Diego Convention Center Held in Room 2 of the F&G Showroom